Skip to main content

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD

Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.

Continue reading

CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD

In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them.

Continue reading

Confronting Knowledge Gaps in Rare Hematologic Malignancies

In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians regarding hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM).  According to the Leukemia and Lymphoma Soc...

Continue reading

Multiple Myeloma Trials and Quality News Reporting With Manni Mohyuddin, MBBS

At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;14) translocation in multiple myeloma, the characterization of survival end points in clinical trials, and ways to improve the quality of news reporting of oncology clinical trials.  

Continue reading

Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD

Oncology Data Advisor™ · Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Jorge Cortes, Director of the Georgia Cancer Center in Augusta, Georgia, sat down with Oncology Data Advisor to discuss his presentation regarding the results of a pivotal phase 2 study in which olutasidenib was studied in patients with relapsed/refractory isocitrate dehydrogenase 1 (IDH1)...

Continue reading

Understanding Clonal Hematopoiesis in Hematologic Malignancies With Rahul Banerjee, MD, Jeremy Meier, MD, and Samuel Rubinstein, MD

Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.

Continue reading

New and Exciting Directions in Leukemia Research: Fellows Forum With Sunil Iyer, MD

Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Sunil Iyer, Chief Hematology/Oncology Fellow at the University of Miami, Florida, discusses his leukemia research, exciting new treatment directions, and what to look forward to in the next several years regarding this field.

Continue reading

Omidubicel-onlv Approved for Reducing Infection and Time to Neutrophil Recovery in Patients With Hematologic Malignancies

The FDA has approved omidubicel-onlv (Omisirge®, Gamida Cell Ltd.) for treatment of adult and pediatric patients 12 and older with hematologic malignancies, to minimize the time to neutrophil recovery and incidence of infection following myeloablative conditioning for umbilical cord transplantation. Approved population: adults and pediatric patients ≥12 with hematologic malignancies Why it matters: "Early-phase studies have demonstrated that ex vivo expansion of umbilical cord blood (UCB) s...

Continue reading

Mosunetuzumab-axgb Approved for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to mosunetuzumab-axgb (Lunsumio™, Genentech) for adult patients with relapsed or refractory follicular lymphoma (FL) who have previously received at least two lines of systemic therapy. "Mosunetuzumab is a CD20 x CD3 T-cell–engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells," wrote L. Elizabeth Budde, MD, PhD, Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of ...

Continue reading

Advocating for Patients During Multiple Myeloma Clinical Trial Design and Post-Protocol: Manni Mohyuddin, MBBS, and Rahul Banerjee, MD

In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, an Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma. 

Continue reading

Advocating for Patients During Multiple Myeloma Clinical Trial Design and Post-Protocol: Manni Mohyuddin, MBBS, and Rahul Banerjee, MD

Oncology Data Advisor™ · Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, an Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myelom...

Continue reading

Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Food for Thought From Urvi Shah, MD, and Rahul Banerjee, MD

Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma. Rah...

Continue reading

Olutasidenib Approved for Acute Myeloid Leukemia

The FDA has granted approval to olutasidenib (Rezlidhia™, Rigel Pharmaceuticals Inc.) for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase 1 gene (IDH1) mutation. Additionally, the FDA granted approval to the Abbott RealTime IDH1 Assay to accurately detect and select patients to receive olutasidenib. Olutasidenib is an inhibitor specific to mutant IDH1. "Mutation of IDH1 occurs in 7% to 14% of patients with AML," wro...

Continue reading

CARG Chemotherapy Toxicity Calculator Found Not Valid for Older Patients With Hematologic Malignancies: Ashley Rosko, MD

Understanding the balance between effective treatments and health-related quality of life is crucial, especially when treating older adults with hematologic malignancies. The Cancer and Aging Research Group (CARG) chemotherapy toxicity calculator has been sufficiently studied and utilized in patients with solid tumors; however, its efficacy in the hematologic malignancy setting was previously unknown. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting &...

Continue reading

Caring for Patients Receiving CAR T-Cell Therapy With Joshua Sasine, MD, PhD

In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  

Continue reading

The Future of MRD in Multiple Myeloma Treatment Decision Making With Rahul Banerjee, MD, and Ben Derman, MD

In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.  

Continue reading

Improving Patient Experiences in Multiple Myeloma With Tiffany Richards, PhD, ANP-BC

At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Oncology Data Advisor spoke with Tiffany Richards, PhD, ANP-BC, Advanced Practice Nurse at MD Anderson Cancer Center, about strategies for optimizing patient experiences during multiple myeloma treatment. Dr. Richards discusses the challenges of treating patients with multiple myeloma, particularly during the COVID-19 pandemic, and shares strategies for promoting adherence and optimizing...

Continue reading

Duvelisib/Romidepsin for Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Steven M. Horwitz, MD

For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Steven M. Horwitz, medical oncologist at Memorial Sloan Kettering Cancer Center, investigated the efficacy of the phosphoinositide-3-kinase inhibitor du...

Continue reading

Polatuzumab Vedotin Plus R-CHP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: John Burke, MD

For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxorubicin/prednisone) for this population. In this interview, one of the study's investigators, Dr. John Burke of Rocky Mountain Cancer Centers and the U...

Continue reading

Addressing Racial Disparities in Clinical Trial Recruitment: Alexis A. Thompson, MD, MPH

One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg School of Medicine, shared her thoughts on strategies for remedying these disparities so that more inclusive care can be provided for patients with h...

Continue reading